Strontium ranelate: New perspectives for the management of osteoporosis

Rheumatology (United Kingdom)

Volumn 48, Issue SUPPL.4, 2009, Pages

  Cortet, Bernard ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

EDITORIAL; FRACTURE; HUMAN; OSTEOPOROSIS;

BONE DENSITY CONSERVATION AGENTS; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; THIOPHENES;

EID: 84864302650     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep277     Document Type: Editorial

References (17)

1. Brennan TC, Rybchyn MS, Halbout P et al. Strontium ranelate effects in human osteoblasts support its uncoupling effect on bone formation and bone resorption. Calcif Tissue Int 2007;80(5 Suppl. 1):S72.
2. Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol 2007;74:438-47.
3. Marie PJ. Strontium ranelate: new insights into its dual mode of action. Bone 2007; 40:S5-8.
4. Mentaverri R, Hurtel AS, Kamel S, Robin B, Brazier M. Extracellular concentrations of strontium directly stimulates osteoclast apoptosis. J Bone Min Res 2003;18:M237.
5. Mentaverri R, Hurtel AS, Wattel A et al. Calcium-sensing receptor mediates ranelateinduced osteoclast apoptosis. Bone 2005;36(Suppl. 2):S403.
6. Arlot ME, Jiang Y, Genant HK et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res 2008;23:215-22.
7. Meunier PJ, Roux C, Ortolani S et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int. Advance access published January 20, 2009, doi: 10.1007/s00198-008-0825-6.
8. Reginster JY, Felsenberg D, Boonen S et al. Effects of long-term strontium ranelate treatment on the risk of non vertebral fractures and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95.
9. Roux C, Fechtenbaum J, Kolta S et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008;67:1736-8.
10. Seeman E, Vellas B, Benhamou C et al. Strontium ranelate reduces the risk of vertebral and non-vertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21:1113-20.
11. Bruyere O, Roux C, Detilleux J et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J clin Endocrinol Metab 2007;92:3076-81.
12. Bruyere O, Roux C, Badurski J et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 2007;12:3041-5.
13. Cummings SR, Karpf DB, Harris F et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
14. Kanis JA, Burlet N, CooperC et al. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2008;19:399-428.
15. Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner res 2002;17:1-10.
16. Sorensen OH, Crawford GM, Mulder H et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6.
17. Seeman E, Devogelaer J-P, Lorenc R et al. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 2008;23: 433-38.